All In Biotech

Drug Trial Radar · NCT02888704

Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Dec 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

13

Actual

Start

Jul 2016

Primary completion

Dec 2017

Study completion Dec 2017

Sponsor

Lead sponsor
EHL Bio Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate safety, tolerance, and efficacy in subjects with over moderately subacute and chronic atopic dermatitis after an intravenous injection of autologous mesenchymal stem cells. The study is composed of two steps. Step 1 is to determine clinically proper dose capacity of the ADSTEM Inj. and step 2 is to evaluate exploratory efficacy of the ADSTEM Inj. at the proper dose.

Conditions

  • Atopic Dermatitis

Interventions

  • ADSTEM Inj. (Adult human mesenchymal stem cells)Drug

    Comparison of different dosages of the drug in the aspect of safety and efficacy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with treatment-related adverse events as assessed by CTCAE version 4.03Time frame: 12 weeks follow-up after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungnam National University Hospital

    Daejeon, Chungcheongnam-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.